Pharmala Biotech Holdings Inc.
MDMA
CNSX
02/28/2025 | 11/30/2024 | ||||
---|---|---|---|---|---|
Revenue | 144.12% | 8.59% | |||
Total Other Revenue | -- | -- | |||
Total Revenue | 144.12% | 8.59% | |||
Cost of Revenue | -- | -- | |||
Gross Profit | 128.06% | -71.69% | |||
SG&A Expenses | 82.98% | 26.48% | |||
Depreciation & Amortization | -5.58% | 28.74% | |||
Other Operating Expenses | -- | -- | |||
Total Operating Expenses | 84.64% | 92.88% | |||
Operating Income | -76.61% | -115.55% | |||
Income Before Tax | -62.65% | -112.64% | |||
Income Tax Expenses | -- | -- | |||
Earnings from Continuing Operations | -62.65% | -112.64% | |||
Earnings from Discontinued Operations | -- | -- | |||
Extraordinary Item & Accounting Change | -- | -- | |||
Minority Interest in Earnings | -- | -- | |||
Net Income | -62.65% | -112.64% | |||
EBIT | -76.61% | -115.55% | |||
EBITDA | -79.33% | -113.93% | |||
EPS Basic | -43.59% | -116.67% | |||
Normalized Basic EPS | -52.17% | -109.09% | |||
EPS Diluted | -43.59% | -116.67% | |||
Normalized Diluted EPS | -52.17% | -109.09% | |||
Average Basic Shares Outstanding | 14.89% | -3.47% | |||
Average Diluted Shares Outstanding | 14.89% | -3.47% | |||
Dividend Per Share | -- | -- | |||
Payout Ratio | -- | -- |